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Introduction
Infertility affects approximately 10–15% of all couples (1).
Spermatogenesis is at fault in about half of them, but its
cause is often covert. Androgens are required for normal
spermatogenesis; however, most infertile men with
impaired spermatogenesis have normal serum androgen
levels. Therefore, attention has turned to the androgen
response apparatus, particularly the androgen receptor
(AR). Mutation of the X-linked AR gene causes a wide
range of clinical androgen insensitivity: complete, when
the external genitalia are female; partial, when they are
sufficiently ambiguous to require corrective surgery; and
mild, when they are phenotypically male. Three surveys
of men with idiopathic infertility have yielded widely dis-
parate frequencies of androgen-binding abnormalities in
cultured genital skin fibroblasts (2–4). Genetic defects of
the AR that cause mild androgen insensitivity with
impaired or preserved spermatogenesis (5–7) are of par-
ticular interest because they may illuminate the fine
structure-function attributes of the AR that permit dif-
ferential regulation of androgen-inducible genes. To this
end, we screened a large group of infertile men with defec-
tive spermatogenesis for abnormalities in the coding seg-
ments of their AR genes. We found 3 unrelated subjects
with the same missense substitution in the COOH-ter-
minal portion of the ligand-binding domain (LBD) of the
AR. One shaves infrequently; another has low-grade but
persistent postpubertal gynecomastia. Unexpectedly, this
novel mutation does not affect the ligand-binding char-
acteristics of the AR; rather, it reduces the transactiva-
tional competence of the AR by impairing interactions
between the receptor domains, binding to androgen
response elements (AREs), and function of the steroid
receptor coactivator TIF2.
Methods
The study population. Our patients presented to infertility clinics
because they could not conceive for at least 2 years. None was
referred with the problem of sexual ambiguity. Two or more
sperm samples were collected at least 3 months apart after 3- to
5-day abstinence and were assessed according to World Health
Organization criteria (8). Patients with abnormal sperm analy-
ses due to obstruction of the genital tract, hypopituitarism,
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Structural changes in the androgen receptor (AR) are one of the causes of defective spermatogenesis.
We screened the AR gene of 173 infertile men with impaired spermatogenesis and identified 3 of them,
unrelated, who each had a single adenine fi guanine transition that changed codon 886 in exon 8 from
methionine to valine. This mutation was significantly associated with the severely oligospermic phe-
notype and was not detected in 400 control AR alleles. Despite the location of this substitution in the
ligand-binding domain (LBD) of the AR, neither the genital skin fibroblasts of the subjects nor trans-
fected cell types expressing the mutant receptor had any androgen-binding abnormality. However, the
mutant receptor had a consistently (approximately 50%) reduced capacity to transactivate each of 2 dif-
ferent androgen-inducible reporter genes in 3 different cell lines. Deficient transactivation correlated
with reduced binding of mutant AR complexes to androgen response elements. Coexpression of AR
domain fragments in mammalian and yeast two-hybrid studies suggests that the mutation disrupts
interactions of the LBD with another LBD, with the NH2-terminal transactivation domain, and with the
transcriptional intermediary factor TIF2. These data suggest that a functional element centered around
M886 has a role, not for ligand binding, but for interdomain and coactivator interactions culminating
in the formation of a normal transcription complex.
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hyperprolactinemia, or markedly raised follicle-stimulating hor-
mone were excluded. Of the remaining 173 patients, 33 had
azoospermia, 84 were severely oligospermic (less than 5 mil-
lion/mL), 36 were moderately oligospermic (5–20 million/mL),
and 20 had only abnormal sperm motility. Control male sub-
jects (n = 100) of proved fertility, no previous infertility history
or treatment, and without any genetic disease were recruited
from the contraceptive clinic. A further 205 (110 men and 95
women) healthy subjects were also screened to determine
whether AR allelic variations exist in the general population.
The mutant subjects CML presented at 31 years of age after
4 years of infertility. He shaves infrequently, approximate-
ly once a week. Right-sided cryptorchidism was corrected
at 7 years of age. Testicular volume was 10 mL bilaterally,
and his sperm count was approximately 0.5 million/mL.
KLH presented at 40 years of age after 7 years of infertility.
He had Tanner grade 2 persistent postpubertal gyneco-
mastia. Testicular volume was 6 mL bilaterally, with sperm
counts around 0.3 million/mL. Secondary sexual develop-
ment was otherwise normal in both subjects. The third
subject, EHS, had a sperm count of 0.7 million/mL. All 3
patients had normal male karyotypes and normal serum
levels of gonadotropins, androgens, sex hormone–binding
globulin, prolactin, and estradiol.
Mutational screening with single-stranded conformational polymor-
phism. DNA was extracted from peripheral blood. Coding seg-
ments and flanking intronic sequences of exons 2–8 of all 173
patients were examined by single-stranded conformational
polymorphism (SSCP) (9). DNA fragments that exhibited dif-
ferential mobilities were sequenced. Exons 2–8 of the patients
(CML, KLH, EHS) with mutant alleles were reexamined by
SSCP to exclude any coexisting mutations that might have been
missed on initial screening. Most of exon 1 of the mutant sub-
jects was screened by SSCP. The 2 highly polymorphic trinu-
cleotide (CAG and GGC) tracts were directly sequenced.
In vivo androgen-binding properties of AR. Fibroblast cultures
were obtained from skin biopsies of subjects and from normal
controls. The androgen-binding properties of the AR were deter-
mined according to standard techniques (10). Finasteride (10–7
M) was added to the cultures to inhibit endogenous 5 a -reduc-
tase activity that might degrade androgens. Scatchard analysis
was performed by plotting specifically bound hormone versus
the bound/free ratio. Kd was determined from the negative slope
of the graph. Bmax was obtained from the intercept of the line on
the x axis. Thermolability was examined by comparing the bind-
ing properties at 32° C or 37° C, and 42° C. A reduction of Bmax of
more than 40% defined thermolability. 
Chase experiments. To determine Kd, the rate constant of dis-
sociation, cell monolayers were preincubated with the radiola-
beled androgens, and the proportion of labeled hormone still
specifically bound after exposure to excess unlabeled hormone
was determined at defined time intervals.
Plasmids
M886V AR. The mutation in our subjects was recreated in a
cDNA fragment by site-directed mutagenesis (6) and then sub-
stituted into the homologous section of an AR expression vec-
tor, pSVhARo. Transactivation domain (TAD) and LBD AR
fragments were formed from AR cDNA by excising fragments
bounded by the unique restriction sites KpnI/EcoRI and
NheI/KpnI, respectively.
Mammalian two-hybrid. The pGAL4DBD-LBD (CLONTECH
Laboratories Inc., Palo Alto, CA) was prepared by amplifying
cDNA encoding the AR LBD (exons 4–8) and ligating in-frame
into the SmaI/HindIII site of pM containing GAL4 DNA-bind-
ing domain. The pVP16AD-ARTAD was made by restricting
pSVhARo with EagI and HindIII to release the fragment encod-
ing amino acids 14–565 of the AR. The 5¢ end of this fragment
was then ligated to a synthetic linker encoding the first 13
amino acids of ARTAD, and the resultant fragment encoding
the entire ARTAD was cloned in-frame with the VP16 activation
domain using pVP16 vector. Plasmid pVP16AD-TIF2 was con-
structed by a double digest of pSG5-TIF2 with HindIII/XbaI fol-
lowed by ligating in-frame to pVP16. The (17m)5-E1bTATA-Luc
reporter vector was obtained by amplifying the 5 GAL4 binding
sites and the adenovirus E1b minimal promoter of pG5CAT and
ligating upstream of the luciferase gene in pGL-basic (Promega
Corp., Madison, Wisconsin, USA) vector.
Yeast two-hybrid. Wild-type (WT) or M886V LBD fragments
including (amino acids 502–919) or excluding (amino acids
659–919) the DNA-binding domain (DBD) were generated by
double digesting the full-length AR vector with KpnI/BamHI
or PvuI/BamHI, respectively. The LBD fragments were cloned
into vectors pAS2-1 and pACT2, which contain the GAL4
DNA-binding domain (amino acids 1–147) and the GAL4
transactivation domain (amino acids 768–881), respectively, to
generate GAL4-AR hybrid constructs. Full-length AR con-
structs were made by excising the AR from pSVhARo.BHEX
using SmaI/BamHI and then ligating the resulting fragment to
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Figure 1
(a) SSCP analyses of family members of 2 probands. Exon 8 fragments
were amplified from genomic DNA and electrophoresed on a PAGE gel
to display SSCP mobility shifts. The probands, CML (lanes 2 and 6) and
KLH (lanes 1 and 5), have a mutant DNA strand (lower arrow) that
migrates faster than the WT allele (upper arrow) from the unaffected sib-
lings (sister of CML, lane 4; brother of KLH, lane 8). Mothers of CML
(lane 3) and KLH (lane 7) have both mutant and WT alleles, indicating
that both women are carriers. (b) Sequencing autoradiogram of a por-
tion of AR exon 8 from patient CML compared with the normal. Three
patients had the same Afi G substitution. (c) Restriction analyses of fam-
ily members of 2 patients (CML, KLH). Exon 8 fragments were amplified
from genomic DNA and restricted with BbrP1. The M886V mutation cre-
ates a new BbrP1 site such that enzymatic digestion results in 2 fragments
(B and C) in the probands (lane 3, CML; lane 5, KLH), whereas normal
alleles (lane 1, sister of CML; lane 4, normal fertile man; lane 7, brother
of KLH) have only 1 fragment (A), measuring 347 bp. Mothers of CML
(lane 2) and KLH (lane 6) display all 3 fragments, indicating their het-
erozygous status. Outer lanes are 123-bp DNA ladders (L).
pAS2-1 and pACT2 that had been similarly digested. All con-
structs were sequenced to confirm the fidelity of the enzymat-
ic manipulations.
Mammalian cell culture and transient transfection. Mutant and
WT plasmids were transfected into COS-7, CV-1, or HeLa cells
using lipofection technique (11). pCMV- b Gal was used to
assess transfection efficiency. In some replicates, radiolabeled
mibolerone (MB) was added to the culture medium and spe-
cific MB-binding activity was determined (6). Transactivation
activity was measured in relative light units (RLU) and nor-
malized to protein content and transfection efficiency.
Immunoblot analyses. Immunoblot analyses were used to study
the effect of the mutation on AR protein production. The rab-
bit polyclonal antibody PG-21, which recognizes the first 21
NH2-terminal amino acids of the human AR, was used to detect
AR protein (12). Mouse mAb SC510 (Santa Cruz Biotechnolo-
gy Inc., Santa Cruz, California, USA) was used to locate
GAL4DBD fusion proteins. Protein-antibody complexes were
subsequently viewed by enhanced chemiluminescence (11).
DNA mobility gel shift assays and quantitation of
androgen-AR complexes bound to AREs
DNA mobility gel shift assays. COS-7 cells were transfected with
WT or mutant AR plasmids, harvested in extraction buffer (20
mM HEPES [pH 7.9], 20% glycerol, 100 mM KCl, 0.2 mM
EDTA) containing protease inhibitors (phenylmethylsulfonyl-
fluoride, leupeptin, aprotinin), lysed by 3 freeze/thaw cycles to
release AR. A consensus synthetic ARE (5 ¢ -CTAGAAGTCTG-
GTACAGGGTGTTCTTTTTGCA-3 ¢ ), served as specific-bind-
ing DNA (13). Two nonspecific competitor oligonucleotides
were used. The first incorporates a WT estrogen response 
element (ERE) from the promoter of the Xenopus vitellogenin
A2 gene: 5 ¢ -GTCCAAAGTCAGGTCACAGTGACCTGAT-
CAAAGTT-3 ¢ ; the second incorporates a transcription factor
Oct2A response element: 5¢ -GTACGGAGTATCCAGCTCCG-
TAGCATGCAAATCCTCTGG-3 ¢ . T4 polynucleotide kinase
and [ g -32P]dATP were used to label the oligonucleotides. Bind-
ing reactions containing 5 m g cell extract, 60 m g BSA, 10% glyc-
erol, 2 mM DTT, 2 m g poly(dI-dC), 0.2 mM EDTA, and 20 mM
HEPES (pH 7.9) in a total volume of 20 m L were preincubated
on ice for 20 minutes. Some reactions contained a 25-fold
excess of unlabeled oligonucleotide as competitor DNA.
Labeled oligonucleotides (~ 0.3 ng, 10,000 cpm) were added and
incubation carried out a further 20 minutes at room tempera-
ture. AR-DNA complexes were resolved by electrophoresis on
5% PAGE gels and autoradiographed. 
Quantitation of androgen-AR complexes bound to AREs. AR
expressed in COS-1 cells was exposed to 3 nM [3H]MB and har-
vested, and aliquots were measured for radioactivity. Each
assay mixture contained 10 m g of poly(dI-dC), a sample of
charcoal-treated supernate with 50,000 dpm of MB-receptor
complexes, and binding buffer to a final volume of 500 m L.
Then we added 150 pmol of 3 ¢ -biotinylated double-
stranded oligonucleotide sequence of the synthetic ARE 
(5¢ -CTAGAAGTCTGGTACAGGGTGTTCTTTTTGCA-biotin),
or MMTV-ARE (5 ¢ -TATGGTTACAAACTGTTCTTAAAA-
biotin) and 50 m L of streptavidin-agarose beads, before con-
tinuing incubation for 2 hours. The beads were collected by
centrifugation, washed three times, and bound radioactivity
was measured by liquid scintillation. Assay mixtures lacking
an ARE bound negligible amounts of radioactivity. Each data
point was the mean of duplicate experiments calculated as a
percentage of binding observed with WT AR (14, 15).
Yeast two-hybrid assay for LBD-LBD interactions. Hybrid GAL4-
AR proteins were expressed in Saccharomyces cerevisiae Y190
containing integrated GAL4 binding sites upstream of the
UASGAL1-lacZ reporter gene. Interaction between hybrid pro-
teins results in a transcriptionally active complex inducing b -
galactosidase activity. Yeast transformation was performed
using the lithium acetate method according to protocols. Yeast
were grown in standard YEDP medium or an appropriate
selective medium in the presence or absence of 1 M methyl-
trienolone (MT). Yeast were harvested, and liquid b -galactosi-
dase assays were performed using o-nitrophenyl- b -D-galacto-
side (ONPG) as a substrate according to standard protocols
with the following modification: the yeast were permeabilized
by incubation in a 0.2% sodium lauryl sarcosinate Z buffer
solution (60 nM Na2HPO4, 40 nM NaH2PO4, 10 mM KCl, 1
mM Mg2SO4, 50 mM b -mercaptoethanol) instead of freeze-
thawing before the addition of ONPG.
Results
Mutations detected in the AR of 3 unrelated oligospermic
patients. Three unrelated patients — CML, KLH, and EHS
— showed differential migration of exon 8 PCR frag-
ments when screened by SSCP. Two subjects, CML and
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Figure 2
Dissociation kinetics of ARs in genital skin fibroblasts. Normal (C, open
circles and bold lines) and mutant (CML, filled circles and normal lines;
KLH, filled squares and thin lines) fibroblast monolayers were exposed
to 2 nM [3H]MB (top), 3 nM [3H]DHT (middle), or 3 nM [3H]T (bot-
tom) at 37 ° C (left) or 42 ° C (right) for 2 hours. The radiolabeled medi-
um was discarded and replaced with one containing 200-fold excess
unlabeled androgen; replicate samples were removed at the indicated
times and assayed for [3H]androgen that was still receptor bound. Each
data point, the mean of 4 replicates, is expressed as a percentage of max-
imum binding at time 0. Vertical axes are on the same logarithmic scale,
except for bottom right panel.
KLH, inherited the mutation from their mothers, who
were heterozygous carriers (Figure 1a). The suspected
fragments were sequenced, and all 3 patients had the
same mutation in exon 8 involving amino acid 886, an
A fi G transition resulting in substitution of valine for
methionine (Figure 1b). This mutation resulted in the
creation of a new BbrP1 restriction site (Figure 1c). All 3
subjects were near-azoospermic, with repeated sperm
counts less than 1 million/mL. CML had 23 codons in
each exon 1 polymorphic trinucleotide repeat tract,
whereas KLH had 21 glutamine and 24 glycine codons,
confirming that the 2 subjects were not genetically relat-
ed. No coexisting mutations were detected in AR exons
1–8 of the 3 patients on SSCP analyses, nor in exon 8
PCR fragments of 400 AR alleles from healthy controls.
The presence of 3 mutations in our 173 infertile patients
and none in 400 control alleles makes it unlikely that
M886V exists in the general population (Fisher’s exact
test, P = 0.027). On the other hand, as the mutations
occur only in a subset of infertile men with severe
oligospermia (n = 84), it is more likely (P = 0.005) that
M886V is significantly associated with the phenotype of
severe oligospermia.
M886V in the LBD had no effect on androgen-binding charac-
teristics. The Kd for dihydrotestosterone (DHT) was 0.31
and 0.52 nM, and the Bmax was 36 and 37 fmol DHT/mg
protein for CML and KLH, respectively, at 37°C for
fibroblast monolayers cultured from scrotal skin biopsies
(normal: Kd, 0.3–0.6 nM; Bmax, 26–43 fmol/mg protein).
Similarly, there were no significant differences in affini-
ty constants for testosterone (T), the Kd for CML being
1.28 nM (normal: ~ 1.8 nM). With MB, Kd for KLH fibrob-
lasts was 0.1 nM and Bmax was 52 fmol/mg protein; with
MT (R1881), Kd was 0.12 nM and Bmax was 52 fmol/mg
protein (normal: Kd, 0.1–0.3 nM; Bmax, 15–50 fmol/mg
protein). When exposed to DHT at 42°C, the Kd and Bmax
values of AR in CML fibroblasts (0.27 nM and 35 fmol
DHT/mg protein, respectively) were no different from the
corresponding values at 37°C, indicating the absence of
thermolability. The experiment was repeated using MB
and MT, with similar results (data not shown). Prolonged
labeling for 15 hours at 37°C with 2 nM MT, or MB, fol-
lowed by a switch to 41 ° C or 42°C for up to 6 hours in
the presence of 100 mM cycloheximide, failed to demon-
strate any difference between mutant and normal cells at
the higher temperatures. Chase experiments were per-
formed to examine the dissociation kinetics of mutant
AR complexes. When chased at 37°C or 42°C, the disso-
ciation rates for T, DHT, and MB were similar for both
normal and mutant fibroblasts (Figure 2). After an 18-
hour incubation with T, the remaining AR complexes dis-
sociated linearly with a k value of 5 (10–3/min) at 37°C.
This value is typical of DHT-receptor complexes and
indicates normal conversion of T to DHT. The AR con-
tent of CML fibroblasts rose from 48 to 104 fmol/mg
protein when incubated with MB for 2 and 20 hours,
respectively, indicating normal receptor upregulation.
Normally, a doubling or greater of specific androgen-
binding activity is observed after overnight incubation
with androgen, presumably because of AR stabilization
by ligand. Likewise, the affinity and dissociation charac-
teristics of androgens bound to mutant receptors
expressed in COS-7 cells were no different from the WT
(data not shown). In aggregate, these experiments, inde-
pendently replicated in 2 laboratories, indicate that the
M886V mutation of the LBD did not change any andro-
gen-binding properties of the receptor.
Impaired transactivation capacity of the mutant receptor. The
mutant receptor, however, had only 50–70% of the trans-
activation capacity of the WT receptor in COS-7 cells
when exposed to various concentrations of T, DHT, and
MB. The ARs encoded by the normal and mutant plas-
mids demonstrated dose-dependent increases in trans-
activation capacity with T, but at all doses from 10 to
300 nM, the transcriptional capacity of M886V AR was
only about half that of the WT (data not shown). The
transactivational defect persisted even with doses of
androgens up to 1 m M (Figure 3). Thus, the mutant AR
had a modest but consistent reduction in its transacti-
vation capability compared with that of the WT, for all 3
androgens, in repeated experiments. Using a cell line
(CV1) that does not express the SV-40 antigen, the trans-
activation defect of the mutant AR was even more evi-
dent. Thus, when 50, 100, and 200 ng of AR cDNA were
used in the transfections, the WT gave 3.1-, 11.1-, and
3.4-fold higher transactivation activity, respectively, com-
pared with the mutant (Figure 4a). Immunoblot analy-
ses showed that AR protein levels were equivalent for
mutant and WT transfections, at all 3 cDNA doses (Fig-
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Figure 3
Transactivation activity of M886V AR with high doses of androgens.
WT (open circles and solid lines) or mutant (filled circles and dotted
lines) receptors were transiently expressed in COS-7 cells and exposed
to increasing doses (nM) of T (a), DHT (b), or MB (c). Transactiva-
tion activity was expressed as fold increase in luciferase activity com-
pared with cells not exposed to androgen. b -galactosidase activity
and protein content were used to normalize for transfection efficien-
cy and cell numbers, respectively. Each data point represents the
mean ± SE of 4 replicates.
ure 4b). Androgen-binding activity of the mutant and
WT AR proteins in COS cells was also similar (data not
shown), confirming that the transactivation defect of
M886V was not due to changes in AR protein levels.
Impaired binding of M886V ligand-AR complexes to AREs.
Both WT and mutant receptors displayed an increase in
ARE binding with the higher hormone dose (Figure 5a,
compare lane 1 with 2, and lane 3 with 4). However the
mutant receptor, despite being present in slightly greater
quantities (Figure 5b), was unable to bind synthetic ARE
as effectively as the WT (Figure 5a, compare lane 7 with 8,
and lane 9 with 10). Addition of excess unlabeled synthet-
ic ARE reduced both WT and mutant signals, with the
mutant band being less prominent than the WT (Figure
5a, lanes 5 and 6). The presence of nonspecific competitor
DNA (ERE; and Oct2a oligonucleotide, the binding site
for a ubiquitous transcription factor) did not reduce the
band shifts, but mutant signal was still less intense than
WT in both instances (Figure 5a, compare lanes 7 with 8
and lane 9 with 10. The specificity of the band shift was
confirmed by the absence of the most prominent band
when radiolabeled ERE was used (Figure 5a, lanes 11 and
12). The ARE-binding deficit of the mutant ligand-AR
complexes was quantified. In a first series of experiments
using 2 different AREs, the mutant receptor had only
57.7% (± 5.17 SE) of the WT DNA-binding capacity (Fig-
ure 5c, left). In a second series of experiments, a slightly
modified technique was used to reduce background
counts, and the DNA-binding defect was even more
marked, with M886V displaying only 38% of the activity
compared with normal controls (Figure 5c, right). In com-
parison, 2 DNA binding–domain mutants, D Phe582 and
D Arg615, displayed less than 20% of normal binding. In
aggregate, the M886V AR had only about half the DNA-
binding activity of the WT, and this defect in DNA bind-
ing was commensurate with the degree of impaired trans-
activation observed, as discussed earlier here.
The mutation affects TAD-LBD interaction. To determine
whether the M886V mutation impairs interaction
between the LBD and TAD, vectors encoding the
COOH-terminal LBD and the NH2-terminal TAD were
constructed and expressed simultaneously in the pres-
ence of an ARE-driven reporter gene (Figure 6a). The
LBD or TAD fragments by themselves did not display
any androgen-inducible reporter gene activity. However,
WT LBD fragment, when coexpressed with the TAD,
resulted in an androgen-dependent increase in luciferase
activity when exposed to physiological doses of DHT,
indicating that AR fragments can interact to yield a func-
tional protein (Figure 6a, left). Mutant LBD fragment,
when coexpressed with TAD, resulted consistently in a
22–25% lower androgen-inducible activity compared
with the WT LBD fragment in 3 independent experi-
ments. Fusion proteins, comprising ARTAD fused to
VP16AD, and ARLBD to the GAL4DBD, were coex-
pressed in HeLa cells, and protein-protein interactions
were measured with a reporter vector containing multi-
ple GAL4 DNA-binding sites in the mammalian two-
hybrid assay (Figure 6b). Interactions between TAD and
LBD were specific and androgen dependent. Differences
between WT and mutant were most evident when
approximately equivalent quantities (50–100 ng) of LBD
and TAD hybrid plasmids were cotransfected (Figure 6b,
left). Mutant LBD fusion protein had only half the activ-
ity of the WT in this assay when exposed to sub-
nanomolar doses of MB (Figure 6b, right). Thus, experi-
ments with AR fragments using an ARE-driven reporter,
and AR fusion proteins using GAL4-driven reporter,
indicated that M886V impaired TAD-LBD interactions.
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Figure 4
(a) Transactivation activity of M886V AR with increasing doses of AR
cDNA. CV1 cells were cotransfected with the indicated amounts of WT
or M886V AR cDNA and the reporter plasmid pMAM-LUC. Each data
point, the mean of triplicates, represents the fold increase in luciferase
activity of cells exposed to 30 nM MB compared with those without
androgen. Bars are ± SE. (b) Immunoblot of WT (W) or mutant (M)
receptors. CV1 cell extracts (10 m g total protein each) depicted in a were
electrophoresed on an SDS-PAGE gel, and AR protein identified with a
specific antibody (PG-21). Films were overexposed to enhance signal for
the low-abundance AR protein.
Table 1
Interactions of AR fusion proteins in the yeast two-hybrid assay
G(TAD)-AR(LBD) G(TAD)-(AR)
G(DBD)-AR(LBD) G(DBD)-AR(LBD)
Experiment WT M886V Experiment WT M886V
1 5.58 ± 0.72 3.03 ± 0.68 1 244 ± 21 51.4 ± 4.5
2 7.08 ± 3.66 3.33 ± 0.29 2 379 ± 193 197 ± 87
3 5.45 ± 2.93 3.55 ± 1.26 3 154 ± 51.4 124 ± 43
Mean 6.03 3.30 Mean 259 124
Yeast GAL4-activation [G(TAD)] and DNA-binding [G(DBD)] domains were fused
to full-length AR or LBD fragment to study interdomain interactions. Data (mean
± SE) represent the fold increase in b -galactosidase activity, in the presence and
absence of 1 m M MB, of 3 independent experiments, each in triplicate.
The mutation affects LBD-LBD interactions. To examine
whether the M886V mutation can affect LBD-LBD inter-
actions, we constructed hybrid expression vectors where-
in full-length or truncated AR fragments were fused to
the GAL4 DNA-binding [G(DBD)] or the GAL4-trans-
activation [G(TAD)] domains in the yeast two-hybrid
assay (Table 1). No androgen-inducible activity was
observed when GAL4-AR hybrid proteins were coex-
pressed with the GAL4 domains [G(DBD) or G(TAD)]
alone (data not shown). Coexpressed G(TAD)-AR(LBD)
and G(DBD)-AR(LBD) hybrid proteins containing the
WT LBD induced a 5- to 7-fold increase in transcrip-
tional activity in the presence of androgen. In contrast,
fusion proteins containing the mutant LBD were con-
sistently only half as transcriptionally active as the WT
in 3 independent experiments, each performed in tripli-
cate. Defective interactions were also observed when a
larger AR fragment, G(TAD)-AR(DBDLBD), was used
(data not shown). Notably, when full-length AR
[G(TAD)-(AR)] fusion protein was coexpressed, interac-
tions were 2 orders of magnitude higher than with trun-
cated AR recombinant proteins lacking ARTAD, indi-
cating the importance of TAD-LBD interactions to the
dimerization process. This increase in magnitude of
interaction may reflect intramolecular LBD-TAD asso-
ciation (16) or the intermolecular effect of the TAD on
the LBD (17). In all these experiments, M886V fusion
proteins were consistently transcriptionally defective,
having only about half the activity of the WT.
M886V disrupts interactions with the coactivator TIF2.
Methionine 886 of the AR is close to residues known to
interact with the steroid receptor coactivator TIF2 (18).
We therefore examined the effect of M886V on coactiva-
tor function in 3 ways. First, we measured the effect of
full-length TIF2 on WT and mutant AR transcriptional
activity; second, the interaction of fusion proteins con-
taining TIF2 and LBD; and third, the effect of full-length
TIF2 on TAD-LBD interactions. Full-length TIF2
enhanced WT AR activity approximately 3-fold in a dose-
dependent manner (Figure 7a, left). However, M886V
was defective and lowered coactivator function by
22–41%. Significant impairment of TIF2 function was
most prominent at a dose of 0.1 nM MB (Figure 7a,
right). When fusion proteins containing GAL4DBD-
ARLBD were coexpressed with VP16AD-TIF2, M886V
caused a mean 37% lower receptor/coactivator interac-
tion with doses of MB from 0.01 to 1 nM (Figure 7b,
left). Impaired interaction of TIF2 with M886V was not
corrected by increasing the amount of TIF2 cDNA (Fig-
ure 7b, right). Defective interactions of mutant LBD
with TIF2 were not due to differences in LBD fusion pro-
tein content, as measured by immunoblots and [3H]MB
binding (Figure 7b, bottom). To determine whether
NH2- and COOH-terminal interactions of the AR were
also regulated by coactivator, full-length TIF2 was coex-
pressed with WT or mutant GAL4DBD-ARLBD and
VP16AD-ARTAD fusion proteins in the mammalian
two-hybrid system. Interactions between the WT LBD
and the TAD fusion proteins were increased up to 20-
fold in the presence of TIF2. M886V disrupted this effect
of TIF2 by up to 28%, consistent with the impaired TAD-
LBD interactions observed previously (Figure 7c).
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Figure 5
(a) DNA mobility gel shift assay. WT (W) or mutant (M) receptors were
expressed in COS-7 cells and exposed to 10 nM (lanes 1 and 2) or 100
nM (lanes 3–12) DHT. Equivalent quantities of immunoreactive AR from
the cell extracts were added to binding reactions containing 32P-labeled
synthetic ARE (lanes 1–10) or ERE (lanes 11 and 12) oligonucleotide
sequences. Excess unlabeled ARE (lanes 5 and 6), ERE (lanes 7 and 8),
or Oct (lanes 9 and 10) oligonucleotides were added as competitor DNA
to demonstrate the specificity of the binding reaction. The dark band at
the bottom represents unbound 32P-labeled DNA. (b) Immunoblot of
WT or mutant receptors used in gel shift assay. Five microliters of repre-
sentative cell extract (used in the gel shift assay depicted in Figure 5a) was
exposed to either 10 or 100 nM of DHT and was separated on an SDS-
PAGE gel. AR protein was identified with a specific antibody (PG-21). (c)
Quantification of binding to AREs. Receptors were expressed in COS
cells, exposed to [3H]MB and equivalent quantities (50,000 dpm) of
[3H]MB-AR complexes incubated with 150 pmol of either biotin-labeled
natural ARE (an ARE from MMTV-LTR) or synthetic ARE in 2 independ-
ent series of experiments. Streptavidin-biotin–bound AREs were collect-
ed by centrifugation, and [3H]MB-labeled receptor bound to the AREs
was quantified by scintillation counting. Known DNA binding–domain
mutants (D F582, D R615) with severe impairment of DNA binding were
used for comparison. In the right panel, background counts were low-
ered by treating the lysate with dextran-coated charcoal and by centrifu-
gation at 100,000 g for 1 hour. Assays using mock-transfected cells
showed minimal background activity. Each data point was the mean of
2 experiments, and bars indicate their range.
Discussion
Earlier studies (2–4, 19, 20) have provided endocrine-bio-
chemical evidence linking oligospermia and azoosper-
mia, with or without other signs of undervirilization, to
quantitative and/or qualitative abnormalities of the AR.
There have been only 2 case reports (6, 21) of AR point
mutations in men with different degrees of impaired
spermatogenesis. This study was undertaken to discov-
er constitutional AR mutations in a series of 173 men
with varying degrees of impaired spermatogenesis.
Among the subset of 84 men with severe, idiopathic
oligospermia, we found 3, unrelated, each of whom had
the same novel AR variant: M886V. The fact that we did
not find the variant among 400 control AR alleles indi-
cated that this was a pathogenic allelic variation. One of
the men shaves infrequently; the other has Tanner grade
2 persistent postpubertal gynecomastia. These facts
strengthened the idea that a cause-and-effect relation-
ship might exist between the AR variant and severe
oligospermia. To prove its pathogenicity, we undertook
the studies, the results of which are discussed later here.
The location of the Met886Val mutation in the LBD of
the AR led us to expect some degree of androgen-bind-
ing abnormality because a nearby mutation, V889M, 3
residues downstream, has been reported to cause nearly
complete androgen insensitivity due to defective andro-
gen-binding capacity (22). Furthermore, all mutations
so far described in exon 8 of the AR manifest some
abnormality of androgen binding (23). To our surprise,
all androgen-binding properties of the M886V in genital
skin fibroblasts of both probands were within normal
limits. Similarly, the androgen-binding properties of the
mutant AR were normal in 2 transfected mammalian cell
lines. Thus, the M886V mutation, although residing in
the hormone-binding domain of the AR, does not affect
the conformation of the ligand-binding pocket of the
LBD. However, the mutant AR was unable to transacti-
vate normally and displayed only 50–70% of the transac-
tivation ability of the WT in 3 different cell lines (COS,
CV-1, HeLa), as measured by natural (MMTV-LTR) or
multimeric ARE reporter genes. All transactivation-
defective LBD mutations reviewed to date (23) have been
associated with some form of androgen-binding abnor-
malities. In this regard, it is striking to note that the
nearby V889M mutation caused nearly complete andro-
gen insensitivity with increased androgen dissociation
kinetics, despite normal equilibrium androgen-binding
affinity (24). The activated mutant receptor had an
impaired ability to bind oligonucleotides containing 2
different AREs: the first, an artificial ARE based on the
consensus DNA-binding site for androgens; the second,
MMTV-LTR, the naturally occurring steroid response
element. Binding to either ARE was approximately 60%
that of the WT. Thus, it is very likely that reduced ARE
binding contributes to the reduced transactivation com-
petence of the M886V AR. However, as discussed later,
faulty intra- and intermolecular interactions of the
mutant AR may, directly or indirectly, be contributory as
well. Mutations such as M886V are particularly interest-
ing, as they can illuminate functional subdomains that
reside in the LBD.
Interactions between the NH2- and COOH-terminal
domains of the AR have been observed using the mam-
malian two-hybrid system (17, 25), and a transcription-
ally active complex forms when truncated proteins hav-
ing only the NH2- and COOH-terminal domains of the
AR are coexpressed in mammalian cells (16). Several lines
of evidence indicate that defective TAD-LBD and LBD-
LBD interactions are important in the pathogenicity of
M886V. M886 in the COOH-terminal region, directly or
indirectly, interacts with the NH2-terminal portion of
the AR. M886V impairs TAD-LBD interactions in both
AR- and GAL4-driven reporter systems. M886V also con-
sistently disrupted LBD-LBD interactions of GAL4-AR
fusion proteins in the yeast two-hybrid assay. These data
indicate that M886 has a role in interactions between the
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Figure 6
(a) Transcription activity of AR fragments. Deletion constructs encoding
the ARTAD (amino acids 1–504) or the ARLBD (amino acids 507–919)
were transiently transfected into CV-1 cells. Transcriptional activity (meas-
ured in RLU) of the WT or M886V LBD fragments, alone or coexpressed
with TAD (1 m g), was measured with a pMAM-LUC in the presence and
absence of indicated amounts DHT (nM) (left). The experiments were
repeated on another 2 occasions using independent plasmid preparations,
and the results were expressed as fold increase in luciferase activity in the
presence and absence of 3 nM DHT (right). (b) Interactions of LBD and
TAD fusion proteins in the mammalian two-hybrid assay. The fusion pro-
teins VP16AD-ARTAD and GAL4DBD-ARLBD were coexpressed in HeLa
cells, and receptor TAD-LBD interactions were measured with (17m)5-
E1bTATA-Luc reporter plasmid. Cells were exposed to increasing doses of
pVP16AD-ARTAD or MB as indicated. Data points represent mean ± SE
of at least 3 replicates and reflect fold increase in luciferase activity of cells
exposed to MB over those not exposed to the androgen.
functional domains of the AR. It is important to note
that the nearby residue, V889, although a part of the lig-
and-binding pocket, also interacts with the TAD (26).
Similarly, mutations of the human estrogen receptor
affecting C530 (27), approximately 5 residues NH2-ter-
minal to the homologue of AR M886, lose DNA-binding
activity but retain normal estradiol affinity. Collectively,
these data suggest strongly that a functional element
centered around residue 886 of the AR has a role, not for
ligand binding, but for interdomain interactions.
Recently, several steroid receptor coactivators (SRCs)
have been characterized that mediate nuclear receptor
interactions with the preinitiation complex and the chro-
matin template (28). The SRC gene family has several
closely related homologues; of these, TIF2 has the great-
est activity with respect to AR (29). Three highly conserved
regions, each containing the nuclear receptor–interacting
motif LXXLL, are located within the nuclear
receptor–interacting domain of TIF2 (Figure 7b). The
LXXLL motifs interact with core motifs in LBDs of
nuclear receptors close to residue 886 of the AR (30).
M886V significantly impairs TIF2 coactivator function in
an AR-driven reporter system and also with chimeric pro-
teins in the mammalian two-hybrid assay. In both sys-
tems, M886V reduces TIF2 coactivation function by
approximately 40%, equivalent to the defects in transacti-
vation, DNA binding, and interdomain interactions
observed. There is evidence that TIF2 interacts with both
the TAD and LBD of steroid receptors, enhances the tran-
scriptional activity of TAD and LBD separately, and has
an additive effect when TAD and LBD are expressed
simultaneously (31). Our data show that TIF2 increases
by approximately 20-fold the interactions between the
TAD and LBD of the AR and that this interaction is dis-
rupted by M886V (Figure 7c). Thus, it is not surprising
that our mutation can affect interdomain interactions
and DNA binding, as TAD-LBD interactions are thought
to be critical for both functions (26). It is known that lig-
and-induced recruitment of an LXXLL motif of SRC-1 to
the retinoic acid receptor (RAR) promotes heterodimer-
ization to the retinoic acid X receptor (RXR) and binding
of a second LXXLL motif molecule to RXR. The 2 adjacent
LXXLL motifs in SRC-1 contact homologous residues in
the LBDs of the RXR-RAR dimers, thereby forming a
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Figure 7
(a) Effect of TIF2 on AR activity in HeLa cells. Mutant or WT AR plasmids were cotransfected with the indicated amounts of cDNA encoding full-
length TIF2, with (+) or without (–) 0.01 nM MB (left). Cells were transfected with 50 ng TIF2 cDNA and exposed to increasing doses of MB (right).
AR activity was measured with a multimeric AR reporter gene (ARE-TATA-Luc). (b) Interactions of TIF2 and ARLBD fragments in the mammalian
two-hybrid assay. The fusion proteins VP16AD-TIF2 and GAL4DBD-ARLBD were coexpressed in HeLa cells, and protein-protein interactions were
measured with (17m)5-E1bTATA-Luc reporter plasmid. Amino acid positions of TIF2 and ARLBD fragments are numbered. Vertical bars within the
TIF2 fragment indicate nuclear receptor–interacting box motifs (LXXLL), and numbers indicate the first L of each consensus motif. In the left panel,
cells were exposed to increasing doses of MB; in the right panel, cells were exposed to increasing doses of the VP16AD-TIF2 expression vector. Data
are expressed as fold increase in luciferase activity with or without 1 nM MB. Bottom panels show an immunoblot of WT (lanes 1–3) and mutant
(lanes 4–6) GAL4DBB-ARLBD fusion proteins ( ~ 51 kDa) from representative cell lysates (10 m g protein per lane) and specific [3H]MB-binding
activity (fmol/mg protein) of cells transfected with WT or mutant GAL4DBB-ARLBD vector. (c) Effect of TIF2 on TAD-LBD interactions in the mam-
malian two-hybrid assay. WT or mutant GAL4DBD-ARLBD fusion protein was coexpressed with VP16AD-ARTAD in HeLa cells, and TAD-LBD inter-
actions were measured with a (17m)5-E1bTATA-Luc reporter plasmid (as in b). The effect of cotransfecting increasing doses of a fourth vector, pSG5-
TIF2, encoding the full-length TIF2 protein, was measured as fold increase in luciferase activity with and without 0.1 nM MB. Data were the mean
± SE of at least 3 replicates.
charge clamp to stabilize the dimerization complex (32).
Our findings that the M886V mutation affects many AR
processes, including TAD-LBD and LBD-LBD interac-
tions, DNA binding, and transactivation competence, are
consistent with the integrative role that coactivators like
TIF2 may have in these post–ligand-binding events.
Because a nearby AR mutation (E897Q) also preserves
ligand binding while disrupting TAD-LBD and LBD-TIF2
interactions (18), our data suggest that M886 contributes
to a functional subdomain of the AR LBD that does not
mediate androgen binding but is important for interaction
with TIF2. This functional dichotomy in the AR LBD is
not implausible considering that intermolecular interac-
tions depend on surface properties, whereas ligand-bind-
ing pockets are buried within the hydrophobic cores of all
steroid receptor LBDs crystallized to date (33). The identi-
fication of other transactivation-defective LBD mutations
(6, 21) that do not affect ligand binding suggests the pos-
sibility that disruption of one or another coactivator activ-
ity may be a common contributor to pathogenesis of severe
oligospermia and male infertility. Given that at least one of
these abnormalities is correctable by hormonal manipula-
tion (6, 21), understanding the pathogenetic mechanisms
may lead to effective therapeutic strategies.
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